Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer

Shen,Qiming; Xu,Zhe; Xu,Shun

doi:10.3892/ijo.2020.5106

Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer

Authors:
- Qiming Shen
- Zhe Xu
- Shun Xu
View Affiliations

Affiliations: Department of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: August 7, 2020 https://doi.org/10.3892/ijo.2020.5106
Pages: 967-979
Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance is a major obstacle in the therapy of malignant tumors, including non‑small cell lung cancer (NSCLC). Long non‑coding RNAs (lncRNAs) have been demonstrated to be involved in chemoresistance. The present study aimed to investigate the role of lung cancer‑associated transcript 1 (LUCAT1) in cisplatin (DDP) resistance in NSCLC. By using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR), it was found that the expression of LUCAT1 was elevated and that of microRNA‑514a‑3p (miR‑514a‑3p) was decreased in DDP‑resistant NSCLC tissues and cells. Functionally, LUCAT1 upregulation enhanced cisplatin resistance by promoting the viability, autophagy and metastasis, and inhibiting the apoptosis of NSCLC cells, as demonstrated by Cell Counting kit‑8 (CCK‑8) assay, western blot analysis, Transwell assay and flow cytometric analysis. LUCAT1 was identified as a sponge of miR‑514a‑3p and uncoordinated‑51‑like kinase 1 (ULK1) was proven to be a target gene of miR‑514a‑3p by bioinformatics analysis, dual‑luciferase reporter assay and RNA immunoprecipitation (RIP) assay. The enhancing effect of miR‑514a‑3p on cisplatin sensitivity was reversed by the elevation of LUCAT1. ULK1 knockdown suppressed cisplatin resistance, while this effect was attenuated by miR‑514a‑3p inhibition. Moreover, LUCAT1 positively regulated ULK1 expression by targeting miR‑514a‑3p. In addition, LUCAT1 knockdown suppressed tumor growth in vivo. On the whole, the findings of the present study demonstrate that LUCAT1 contributes to the resistance of NSCLC cells to cisplatin by regulating the miR‑514a‑3p/ULK1 axis, elucidating a novel regulatory network in cisplatin resistance in NSCLC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E and Anderson BO: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncol. 4:1553–1568. 2018. View Article : Google Scholar : PubMed/NCBI
3	Heist RS and Engelman JA: SnapShot: Non-small cell lung cancer. Cancer Cell. 21:448.e22012. View Article : Google Scholar : PubMed/NCBI
4	Hirsch FR, Suda K, Wiens J and Bunn PA Jr: New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 388:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
5	Fennell D, Summers Y, Cadranel J, Benepal T, Christoph D, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry D: Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev. 44:42–50. 2016. View Article : Google Scholar : PubMed/NCBI
6	Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP and Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 350:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
7	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:4462018. View Article : Google Scholar : PubMed/NCBI
8	Schmitz SU, Grote P and Herrmann BG: Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 73:2491–2509. 2016. View Article : Google Scholar : PubMed/NCBI
9	Ge P, Cao L, Yao YJ, Jing RJ, Wang W and Li HJ: lncRNA FOXD2-AS1 confers cisplatin resistance of non-small-cell lung cancer via regulation of miR185-5p-SIX1 axis. Onco Targets Ther. 12:6105–6117. 2019. View Article : Google Scholar :
10	Liu MY, Li XQ, Gao TH, Cui Y, Ma N, Zhou Y and Zhang GJ: Elevated HOTAIR expression associated with cisplatin resistance in non-small cell lung cancer patients. J Thorac Dis. 8:3314–3322. 2016. View Article : Google Scholar
11	Wang P, Chen D, Ma H and Li Y: LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis. Onco Targets Ther. 10:5137–5149. 2017. View Article : Google Scholar : PubMed/NCBI
12	Dragomir MP, Knutsen E and Calin GA: SnapShot: Unconventional miRNA functions. Cell. 174:1038–1038.e1. 2018. View Article : Google Scholar : PubMed/NCBI
13	Fujita Y, Yagishita S, Hagiwara K, Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Tsuta K, Nokihara H, Tamura T, et al: The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol The. 23:717–727. 2015.
14	Bian B, Pan X, Yang JS, Wang ZX and De W: Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res. 30:202011. View Article : Google Scholar : PubMed/NCBI
15	Gao Y, Fan X, Li W, Ping W, Deng Y and Fu X: miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124. Biochem Biophys Res Commun. 446:179–186. 2014. View Article : Google Scholar : PubMed/NCBI
16	Jin F, Wang Y, Li M, Zhu Y, Liang H, Wang C, Wang F, Zhang CY, Zen K and Li L: MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death Dis. 8:e25402017. View Article : Google Scholar : PubMed/NCBI
17	Liu Z, Shi A, Song D, Han B, Zhang Z, Ma L, Liu D and Fan Z: Resistin confers resistance to doxorubicin-induced apoptosis in human breast cancer cells through autophagy induction. Am J Cancer Res. 7:574–583. 2017.PubMed/NCBI
18	Wang X, Lan Z, He J, Lai Q, Yao X, Li Q, Liu Y, Lai H, Gu C and Yan Q: LncRNA SNHG6 promotes chemoresistance through ULK1-induced autophagy by sponging miR-26a-5p in colorectal cancer cells. Cancer Cell Int. 19:2342019. View Article : Google Scholar : PubMed/NCBI
19	Zhao Z, Li J, Jiang Y, Xu W, Li X and Jing W: CLDN1 increases drug resistance of non-small cell lung cancer by activating autophagy via up-regulation of ULK1 phosphorylation. Med Sci Monit. 23:2906–2916. 2017. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
21	Du Z, Sun T, Hacisuleyman E, Fei T, Wang X, Brown M, Rinn JL, Lee MG, Chen Y, Kantoff PW and Liu XS: Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer. Nat Commun. 7:109822016. View Article : Google Scholar : PubMed/NCBI
22	Kartha RV and Subramanian S: Competing endogenous RNAs (ceRNAs): New entrants to the intricacies of gene regulation. Front Genet. 5:82014. View Article : Google Scholar : PubMed/NCBI
23	Deng H, Zhang J, Shi J, Guo Z, He C, Ding L, Tang JH and Hou Y: Role of long non-coding RNA in tumor drug resistance. Tumor Biol. 37:11623–11631. 2016. View Article : Google Scholar
24	Majidinia M and Yousefi B: Long non-coding RNAs in cancer drug resistance development. DNA Repair (Amst). 45:25–33. 2016. View Article : Google Scholar
25	Zheng ZG, Xu H, Suo SS, Xu XL, Ni MW, Gu LH, Chen W, Wang LY, Zhao Y and Tian B: The essential role of H19 contributing to cisplatin resistance by regulating glutathione metabolism in high-grade serous ovarian cancer. Sci Rep. 6:260932016. View Article : Google Scholar : PubMed/NCBI
26	Han Z and Shi L: Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis. Biochem Biophys Res Commun. 495:947–953. 2018. View Article : Google Scholar
27	Wang W, Dong M, Zhang W and Liu T: Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2. Eur Rev Med Pharmacol Sci. 23:5229–5234. 2019.PubMed/NCBI
28	Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, et al: Autophagy in malignant transformation and cancer progression. EMBO J. 34:856–880. 2015. View Article : Google Scholar : PubMed/NCBI
29	Yang Y, Jiang C, Yang Y, Guo L, Huang J, Liu X, Wu C and Zou J: Silencing of LncRNA-HOTAIR decreases drug resistance of Non-small cell lung cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1. Biochem Biophys Res Commun. 497:1003–1010. 2018. View Article : Google Scholar : PubMed/NCBI
30	Xiong H, Ni Z, He J, Jiang S, Li X, Gong W, Zheng L, Chen S, Li B and Zhang N: LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. 36:35282017. View Article : Google Scholar : PubMed/NCBI
31	Jin L, Li Y, Zhang Z, He T, Hu J, Liu J, Chen M, Gui Y, Yang S and Mao X: miR-514a-3p functions as a tumor suppressor in renal cell carcinoma. Oncol Lett. 14:5624–5630. 2017.PubMed/NCBI
32	Kim J, Kundu M, Viollet B and Guan KL: AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 13:1322011. View Article : Google Scholar : PubMed/NCBI
33	Tang F, Hu P, Yang Z, Xue C, Gong J, Sun S, Shi L, Zhang S, Li Z and Yang C: SBI0206965, a novel inhibitor of Ulk1, suppresses non-small cell lung cancer cell growth by modulating both autophagy and apoptosis pathways. Oncol Rep. 37:3449–3458. 2017. View Article : Google Scholar : PubMed/NCBI